NewslettersHuman Immunology NewsIntestinal Cell NewsPrometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase II Study in Ulcerative ColitisBy Danielle Corrigan - July 18, 20220147Prometheus Biosciences, Inc. announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase II study of PRA023 in ulcerative colitis.[Prometheus Biosciences, Inc.]Press Release